UK's NICE isn't convinced by Merck's Keytruda in head and neck cancer
There may be 33 new cases of head and neck cancer in the United Kingdom each day, but the region’s cost-effectiveness watchdog NICE is not convinced by the data supporting Merck’s flagship immunotherapy Keytruda in the patient population.
On Wednesday the agency said it was not recommending Keytruda for patients with untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC), citing uncertainty that the trial evidence supporting the drug does not reflect the current treatment paradigm in England’s NHS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.